Mirum Pharmaceuticals

192 articles about Mirum Pharmaceuticals

• Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

  11/20/2023

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it is scheduled to present at the 6th annual Evercore ISI HealthCONx Conference on Tuesday, November 28th 2023 at 3:25 pm ET, as well as 1x1 meetings.

• Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

  11/13/2023

  Mirum Pharmaceuticals, Inc. announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases annual meeting in Boston, Massachusetts.

• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 10, 2023

  11/10/2023

  Mirum Pharmaceuticals, Inc. announced that on November 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 20,000 shares of common stock and 10,000 restricted stock units to five new employees under Mirum’s 2020 Inducement Plan.

• Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference

  11/3/2023

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it is scheduled to participate in a fireside chat at the 2023 UBS Biopharma Conference on Wednesday, November 8th 2023 at 2:00 pm ET, as well as 1x1 meetings.

• Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/2/2023

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for third quarter 2023 and provided a business update.

• Mirum Pharmaceuticals to Present New Data at The Liver Meeting®

  10/30/2023

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that data from its LIVMARLI and volixibat programs will be presented at The Liver Meeting.

• Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

  10/27/2023

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2023 financial results on Thursday, November 2nd, 2023.

• Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

  10/17/2023

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the Supplemental New Drug Application (sNDA) for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC).

• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 11, 2023

  10/11/2023

  Mirum Pharmaceuticals, Inc. announced that on October 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 92,050 shares of common stock and 46,030 restricted stock units to 12 new employees under Mirum’s 2020 Inducement Plan.

• Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

  10/7/2023

  Mirum Pharmaceuticals, Inc. announced the presentation of a series of analyses demonstrating further benefit of LIVMARLI® oral solution in patients with cholestatic pruritus associated with Alagille syndrome and for patients with progressive familial intrahepatic cholestasis, two rare debilitating liver diseases.

• Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis

  10/2/2023

  Mirum Pharmaceuticals, Inc. today announced positive data from the Phase 3 RESTORE study evaluating Chenodal® (chenodiol) tablets in 13 adult patients with cerebrotendinous xanthomatosis, or CTX.

• Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

  9/26/2023

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that data from its LIVMARLI ® (maralixibat) oral solution studies as well as data from real- world experience will be presented at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) annual meeting taking place October 4-7, 2023, in San Diego, California.

• Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference

  9/21/2023

  Mirum Pharmaceuticals, Inc. today announced that it is scheduled to participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on Thursday, September 28th 2023 at 11:30 am ET, as well as 1x1 meetings.

• Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer

  9/11/2023

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Eric Bjerkholt as chief financial officer (CFO).

• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 09, 2023

  9/9/2023

  Mirum Pharmaceuticals, Inc. announced that on September 8, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 174,000 shares of common stock and 91,000 restricted stock units to 21 new employees under Mirum’s 2020 Inducement Plan.

• Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - September 6, 2023

  9/6/2023

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences.

• Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

  9/5/2023

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”).

• Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

  9/5/2023

  Travere Therapeutics, Inc. and Mirum Pharmaceuticals, Inc. announced the completion of the previously announced sale of Travere’s bile acid product portfolio that includes Cholbam® and Chenodal®, two medications addressing rare diseases in high-need settings.

• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 11, 2023

  8/11/2023

  Mirum Pharmaceuticals, Inc. announced that on August 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,200 shares of common stock and 17,100 restricted stock units to six new employees under Mirum’s 2020 Inducement Plan.

• Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/3/2023

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2023 and provided a business update.